Table 1 Bone marrow absorbed dose (mGy/GBq) for the 14 therapy cycles that were evaluated in this study
From: Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT
Cycle | Blood based dosimetry | Imaging based—5 time points, 8–10 vertebrae (T8–L5) | Imaging based—5 time points, 3 vertebrae (L3–L5) | Imaging based—2 time points, 8–10 vertebrae (T8–L5) | Imaging based—2 time points, 3 vertebrae (L3–L5) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
D (mGy/GBq) | u(D) (%) | D (mGy/GBq) | u(D) (%) | D (mGy/GBq) | u(D) (%) | D (mGy/GBq) | u(D) (%) | D (mGy/GBq) | u(D) (%) | |
1 | 11.7 | 19.4 | 14.4* | 18.5 | 13.3$ | 20.5 | 16.6* | 26.7 | 13.8$ | 27.8 |
2 | 15.3 | 24.2 | 12.4 | 20.4 | 12.2 | 24.9 | 14.7 | 26.7 | 12.8 | 27.8 |
3 | 13.6 | 28.3 | 26.4 | 18.7 | 22.4 | 26.4 | 25.6 | 18.8 | 19.2 | 26.4 |
4 | 20.1 | 24.2 | 35.5 | 11.0 | 13.4 | 16.5 | 37.4 | 26.7 | 12.3 | 27.8 |
5 | 25.5 | 14.9 | 29.1* | 19.7 | 15.7 | 19.6 | 32.7* | 18.8 | 23.2 | 26.4 |
6 | 16.4 | 38.4 | 19.5 | 11.6 | 14.9 | 15.9 | 19.7 | 18.8 | 13.6 | 26.4 |
7 | 20.0 | 23.3 | 20.5 | 15.1 | 14.7 | 20.0 | 20.7 | 18.8 | 17.3 | 26.4 |
8 | 18.3 | 47.2 | 25.9# | 18.0 | 17.0 | 19.1 | 25.9# | 18.8 | 15.3 | 26.4 |
9 | 17.9 | 35.1 | 23.9* | 20.2 | 24.1 | 17.8 | 26.0* | 18.8 | 22.7 | 26.4 |
10 | 18.8 | 33.5 | 44.2# | 15.3 | 48.1 | 14.2 | 42.7# | 26.7 | 46.9 | 27.8 |
11 | 14.7 | 54.2 | 34.9 | 18.2 | 30.9 | 17.0 | 33.7 | 26.7 | 13.6 | 27.8 |
12 | 14.2 | 19.8 | 27.8* | 18.1 | 27.5 | 21.0 | 35.1* | 26.7 | 28.9 | 27.8 |
13 | 16.3 | 37.5 | 23.8* | 18.9 | 17.9 | 21.9 | 24.4* | 26.7 | 16.3 | 27.8 |
14 | 17.6 | 34.8 | 17.5# | 15.6 | 13.1$ | 4.5 | 20.2# | 26.7 | 14.0$ | 27.8 |
Mean ± SD | 17.2 ± 3.4 | 31.1 ± 10.7 | 25.4 ± 8.7 | 17.1 ± 3.0 | 20.4 ± 9.9 | 18.5 ± 5.2 | 26.8 ± 8.4 | 23.3 ± 4.1 | 20.6 ± 9.7 | 27.2 ± 0.7 |